High Court Snubs Teva Bid To Stay Copaxone Invalidity Ruling
The U.S. Supreme Court's chief justice on Wednesday denied Teva Pharmaceuticals USA Inc.'s request to stay a lower court's invalidation of patents for Teva's lucrative multiple sclerosis drug Copaxone, enabling Mylan...To view the full article, register now.
Already a subscriber? Click here to view full article